The Journal of Infectious Diseases · 2000 · 85 citations · 9 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyConjugate VaccinesImmunization In InfancyInfant ImmunizationPediatric ImmunizationVaccinationVaccine-preventable DiseasesCapsular Polysaccharide ImmunologyCapsular PolysaccharidesHaemophilus Influenzae Type B Conjugate VaccinesHaemophilus Influenzae Type B DiseaseImmune Responses To Early-life VaccinationPediatric VaccinationVaccine Effectiveness In Infancy
Concentrations of serum anti-Haemophilus influenzae type b (anti-Hib) capsular polysaccharide (CPS) >/=0.15 and >/=1.0 microgram/mL are widely used as surrogates for protection against invasive Hib disease. However, the relationship between serum anti-Hib CPS following immunization and protection against colonization is not known, making it difficult to evaluate new Hib vaccines or combination vaccines. In the Dominican Republic, nasopharyngeal swabs were collected from 546 9-month-old infants who had received Hib conjugate vaccine at ages 2, 4, and 6 months and from 600 unvaccinated infants of the same age. The prevalence of Hib colonization was lower among vaccinated infants than among unvaccinated infants (0.9% vs. 2.3%). Among vaccinated infants, protection against colonization was significantly correlated with anti-Hib CPS concentrations >/=5 microgram/mL 1 month following the third dose of vaccine. These results suggest that the concentration of serum anti-Hib CPS needed for protection against colonization is greater than that needed for protection for invasive disease.
9